No Data
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Takeda Pharmaceutical: Revised Extraordinary Report
ADR Japanese stock rankings - general Sell pressure including Yuucho Bank, Chicago down 145 yen compared to Osaka at 39,255 yen.
Japanese stocks of ADR (American Depositary Receipt) compared to the Tokyo Stock Exchange (calculated at 153.48 yen per dollar) include Yu-cho Bank <7182>, SoftBank Group <9984>, Nidec <6594>, Renesas <6723>, Sony Group Corp <6758>, Murata Manufacturing <6981>, DAIKIN INDUSTRIES, LTD. Unsponsored ADR <6367>, all of which have declined, indicating a general trend towards Sell. The clearing price for Chicago Nikkei 225 Futures is down 145 yen from the Osaka daytime price, now at 39,255 yen. The U.S. stock market has fallen. The Dow Inc decreased by 267.58 dollars, now at 43,449.
Takeda Pharmaceutical (TAK.US) CD38 monoclonal antibody has been approved for clinical use again in China.
Takeda Pharmaceutical's CD38 monoclonal antibody has been approved for clinical use in China again.
Regarding the launch of the strategic partnership "Project Soten" between Takeda Pharmaceutical and Tohoku Universities to accelerate the research and development of Innovative Drugs.
On December 17, 2024, Takeda Pharmaceuticals Sp Adr and Tohoku University announced the launch of a strategic alliance "Project Sōten" to accelerate research and development of Innovative Drugs - Building an advanced clinical trial acceleration model aimed at improving medical access for regional patients and strengthening domestic drug development capabilities - Accelerating the establishment of a medical network and healthcare data infrastructure centered on Tohoku University Hospital, promoting research and development of new drugs and treatments through integrated analysis, and contributing to the world from Tohoku.
Takeda Pharmaceutical Unveils $10 Billion-$20 Billion Late-Stage Pipeline
No Data
